BostonGene announces strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics

CAR-T Digest - August 2020

Weekly Digest - February 2026

17 February 2026: BostonGene announces strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics

BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven multimodal analytics into an antibody-drug conjugate development program, aiming to enhance precision clinical development and response prediction
The partnership will leverage BostonGene’s AI foundation models for tumor and immune biology to move beyond traditional exploratory biomarker analysis and generate decision-ready insights that directly inform patient selection, translational strategy, and development prioritization
By creating digital twin representations from extensive multiomic and histopathologic patient datasets, the platform is designed to identify biological signatures that distinguish responders from non-responders, enabling more precise subgroup definition and benchmarking against existing standards of care
These advanced analytics are also expected to clarify resistance mechanisms and tumor microenvironment dynamics, supporting optimized trial design and more targeted clinical positioning of investigational ADC assets
Through this collaboration, both companies aim to accelerate development timelines, reduce uncertainty in clinical decision-making, and strengthen differentiation strategies for next-generation ADC therapies in oncology